Examination of Musculoskeletal System Problems, Pain and Quality of Life Related to Working Conditions in Chiropractors

March 7, 2025 updated by: AYCAN ÇAKMAK REYHAN, Istanbul Bilgi University
This research aims to investigate musculoskeletal problems and pain, as well as their effects on the quality of life, arising from the working conditions of chiropractors in their workplaces. Additionally, it is intended to conduct a detailed analysis of working conditions in chiropractors' work environments to identify existing problems, establish the cause-and-effect relationship between musculoskeletal problems, pain, and these conditions, conduct studies to improve chiropractors' work environments, and demonstrate the positive effects of improving working conditions on the quality of life and professional performance of chiropractors. Within this scope, the physical layout of chiropractors' work environments, ergonomic factors, and workplace conditions will be analyzed. Musculoskeletal problems experienced by chiropractors will be identified, and research will be conducted on pain and musculoskeletal disorders associated with workplace factors. Furthermore, the effects of working conditions on the quality of life of chiropractors will be evaluated.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Istanbul Bilgi University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Professionals actively working as chiropractors

Description

Inclusion Criteria:

  • Male and female physiotherapists between the ages of 25-45, with at least 1 year of chiropractic experience, will be selected

Exclusion Criteria:

  • Having practiced chiropractic for less than 1 year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The Visual Analog Scale (VAS)
Time Frame: 1 mount
VAS is a measurement tool commonly used to assess subjective characteristics or experiences, particularly pain intensity. It typically consists of a straight line, usually 10 centimeters in length, with one end representing the extreme of the characteristic being measured (e.g., "no pain" or "worst pain imaginable") and the other end representing the opposite extreme. Participants are asked to mark on the line the point that best represents their experience. This mark's distance from the zero point (e.g., "no pain") is then measured to quantify the characteristic being assessed. For pain intensity, the distance marked by the participant correlates with the severity of their pain, with longer distances indicating more severe pain. The VAS is a simple yet effective tool for quantifying subjective experiences and is widely used in clinical settings and research studies to assess various factors such as pain intensity, mood, and well-being.
1 mount
SF-36 Short Form 36 Health Survey,
Time Frame: 1 mount
The SF-36, or Short Form 36, is a widely used questionnaire designed to assess an individual's health-related quality of life. It consists of 36 questions that cover eight different health domains: physical functioning, role limitations due to physical health problems, bodily pain, general health perceptions, vitality (energy/fatigue), social functioning, role limitations due to emotional problems, and mental health (psychological distress and psychological well-being). Each domain is scored separately, and the scores can be aggregated to produce two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). These summary measures provide an overall assessment of physical and mental health status, respectively. The SF-36 is a valuable tool in clinical research and healthcare settings for evaluating patients' overall health status, tracking changes over time, and comparing different patient populations.
1 mount

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The Beck Depression Inventory (BDI)
Time Frame: 1 mount
BDI), also known as the Beck Depression Scale, is a self-report questionnaire designed to measure the severity of depression symptoms in individuals. Beck, the BDI consists of 21 items that assess various symptoms commonly associated with depression, such as sadness, guilt, fatigue, changes in appetite or sleep patterns, and suicidal thoughts.Each item on the scale presents a statement describing a particular symptom, and individuals are asked to rate how much they have been experiencing each symptom over a specific time frame, typically the past two weeks. Responses are scored on a scale ranging from 0 to 3, with higher scores indicating greater severity of depressive symptoms.The total score on the BDI provides an overall measure of depression severity, with higher scores indicating more severe depression.
1 mount

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Bilgi University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 25, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 25, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 25, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 19, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 19, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 25, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 7, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IstanbulBuu

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings